Related Experiment Videos
Acyclovir monotherapy versus acyclovir plus beta-interferon in focal viral encephalitis in children
U Wintergerst1, B H Belohradsky
1Universitäts-Kinderklinik, Ludwig-Maximilians-Universität, München, Germany.
Infection
|July 1, 1992
Summary
Combination therapy of acyclovir and beta-interferon shows promise for severe viral encephalitis, significantly reducing mortality and sequelae in specific patient subgroups. This approach offers improved outcomes for difficult-to-treat cases.
Area of Science:
- Neurology
- Virology
- Pharmacology
Background:
- Severe focal viral encephalitis, often caused by herpes simplex virus (HSV), has high mortality and morbidity despite standard acyclovir (ACV) treatment.
- ACV is ineffective against many viral encephalitis pathogens, highlighting the need for alternative or adjunctive therapies.
- Beta-interferon (beta-IFN) possesses a broad antiviral spectrum, and in vitro studies suggest synergistic effects with ACV against HSV.
Purpose of the Study:
- To evaluate the efficacy of combining acyclovir (ACV) with beta-interferon (beta-IFN) compared to ACV monotherapy for treating severe viral encephalitis.
- To identify patient subgroups that may benefit most from combination antiviral therapy.
Main Methods:
- A retrospective study involving 301 pediatric patients with viral encephalitis across 278 West German children's hospitals.
- Patients received either ACV alone (n=179) or a combination of ACV plus beta-IFN (n=35).
- Outcomes were analyzed, with a specific focus on a subgroup with severe focal encephalitis indicated by temporal lobe low-density areas on CT scans.
Main Results:
- No significant overall difference in outcomes was observed between ACV monotherapy and the combination therapy group.
- In a subgroup of 41 patients with severe focal encephalitis, combination therapy with ACV plus beta-IFN significantly reduced sequelae and mortality (p=0.014) compared to ACV alone.
- The study identified a potential benefit of combination therapy in a specific, severe presentation of viral encephalitis.
Conclusions:
- While ACV remains a standard treatment, combination therapy with beta-IFN may offer improved outcomes for select patients with severe focal viral encephalitis.
- Further prospective studies are warranted to confirm the benefits of ACV and beta-IFN combination therapy in specific viral encephalitis populations.
- Targeted application of combination therapy could improve patient prognosis in severe cases.